AR and prostate carcinoma: Prostate cancer cells and CAFs express the androgen receptor (AR), and when the AR signaling is therapeutically inhibited in CAFs, it increases the expression and release of both CCL2 and CXCL8 cytokines, which exert pacracrine signaling in cancer cells of the prostate, promoting cell migration and invasion [196].